

Shilpa Medicare Limited



Innovating for
affordable healthcare

Manufacturers and Exporters of Bulk Drugs

12-6-214/A1, Hyderabad Road,
RAICHUR - 584 135. Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91-8532-238876

CIN No: L85110KA1987PLC008739

E-mail : info@vbshilpa.com Website : www.vbshilpa.com

Dated: 26 February, 2020

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India
Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

We hereby inform that the US FDA conducted Good Manufacturing Practices (GMP) inspection of Shilpa Medicare Ltd's Finished Dosage Formulation Facility (Sterile and Non-sterile) located at S-20 to S-26, Pharmaceutical Formulations SEZ, TSIIC, Jadcherla, Telangana State, India from 13-25, Feb 2020. At the conclusion of inspection, the Agency issued Form 483, with 15 observations. The company is preparing responses to the observations, which will be submitted to the Agency within 15 business days. The company is committed to address these observations promptly.

With Regards,

For **SHILPA MEDICARE LIMITED**


V V Krishna Chaitanya
Company Secretary
M.No. 49415

